Markets
H.C. Wainwright Reiterates Invivyd Stock Rating: What Trial Progress Means for Traders
H.C. Wainwright has reiterated its rating on Invivyd as clinical trial momentum builds, keeping the biotech name firmly on the radar of risk-on traders and speculative investors in mid-2026.